Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.83 Million PLN | -48.29% |
| 2022 | 19.02 Million PLN | 25.04% |
| 2021 | 15.21 Million PLN | 53.16% |
| 2020 | 9.93 Million PLN | -10.51% |
| 2019 | 11.09 Million PLN | -14.88% |
| 2018 | 13.04 Million PLN | 4.23% |
| 2017 | 12.51 Million PLN | -21.38% |
| 2016 | 15.91 Million PLN | -8.92% |
| 2015 | 17.47 Million PLN | 23.67% |
| 2014 | 14.12 Million PLN | -0.06% |
| 2013 | 14.13 Million PLN | 54.85% |
| 2012 | 9.13 Million PLN | 4.01% |
| 2011 | 8.77 Million PLN | 13.94% |
| 2010 | 7.7 Million PLN | 20.77% |
| 2009 | 6.37 Million PLN | 67.45% |
| 2008 | 3.8 Million PLN | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 10 Thousand PLN | -99.9% |
| 2024 Q2 | 148 Thousand PLN | 1380.0% |
| 2023 Q1 | 4.73 Million PLN | -22.97% |
| 2023 Q3 | 5000.00 PLN | 100.11% |
| 2023 Q2 | -4.57 Million PLN | -196.5% |
| 2023 Q4 | 9.66 Million PLN | 193220.0% |
| 2023 FY | 9.83 Million PLN | -48.29% |
| 2022 Q3 | 4.55 Million PLN | -2.88% |
| 2022 Q2 | 4.69 Million PLN | 29.34% |
| 2022 Q4 | 6.15 Million PLN | 35.04% |
| 2022 FY | 19.02 Million PLN | 25.04% |
| 2022 Q1 | 3.62 Million PLN | -18.22% |
| 2021 Q2 | 3.48 Million PLN | 5.7% |
| 2021 FY | 15.21 Million PLN | 53.16% |
| 2021 Q4 | 4.43 Million PLN | 10.93% |
| 2021 Q3 | 3.99 Million PLN | 14.69% |
| 2021 Q1 | 3.29 Million PLN | 29.34% |
| 2020 Q1 | 2.53 Million PLN | 5.8% |
| 2020 Q2 | 1.83 Million PLN | -27.51% |
| 2020 Q4 | 2.54 Million PLN | -15.4% |
| 2020 FY | 9.93 Million PLN | -10.51% |
| 2020 Q3 | 3.01 Million PLN | 64.02% |
| 2019 Q2 | 2.11 Million PLN | -34.26% |
| 2019 Q4 | 2.39 Million PLN | -29.08% |
| 2019 FY | 11.09 Million PLN | -14.88% |
| 2019 Q1 | 3.21 Million PLN | -0.43% |
| 2019 Q3 | 3.37 Million PLN | 59.82% |
| 2018 Q3 | 3.14 Million PLN | 6.13% |
| 2018 Q4 | 3.22 Million PLN | 2.51% |
| 2018 FY | 13.04 Million PLN | 4.23% |
| 2018 Q2 | 2.96 Million PLN | -19.72% |
| 2018 Q1 | 3.69 Million PLN | 8.1% |
| 2017 FY | 12.51 Million PLN | -21.38% |
| 2017 Q2 | 3.52 Million PLN | 31.08% |
| 2017 Q1 | 2.68 Million PLN | -44.25% |
| 2017 Q3 | 2.88 Million PLN | -18.17% |
| 2017 Q4 | 3.41 Million PLN | 18.63% |
| 2016 Q3 | 4.47 Million PLN | 7.89% |
| 2016 FY | 15.91 Million PLN | -8.92% |
| 2016 Q4 | 4.82 Million PLN | 7.76% |
| 2016 Q2 | 4.14 Million PLN | 67.52% |
| 2016 Q1 | 2.47 Million PLN | -49.7% |
| 2015 Q1 | 4.02 Million PLN | -2.11% |
| 2015 Q3 | 4.71 Million PLN | 23.79% |
| 2015 Q4 | 4.92 Million PLN | 4.35% |
| 2015 FY | 17.47 Million PLN | 23.67% |
| 2015 Q2 | 3.8 Million PLN | -5.46% |
| 2014 Q4 | 4.11 Million PLN | 18.58% |
| 2014 Q2 | 2.58 Million PLN | -34.84% |
| 2014 Q1 | 3.96 Million PLN | 17.02% |
| 2014 FY | 14.12 Million PLN | -0.06% |
| 2014 Q3 | 3.47 Million PLN | 34.48% |
| 2013 Q2 | 3.82 Million PLN | 22.12% |
| 2013 Q4 | 3.38 Million PLN | -10.78% |
| 2013 FY | 14.13 Million PLN | 54.85% |
| 2013 Q1 | 3.13 Million PLN | 23.69% |
| 2013 Q3 | 3.79 Million PLN | -0.84% |
| 2012 FY | 9.13 Million PLN | 4.01% |
| 2012 Q3 | 2.55 Million PLN | 0.0% |
| 2012 Q4 | 2.53 Million PLN | -0.82% |
| 2011 FY | 8.77 Million PLN | 13.94% |
| 2010 FY | 7.7 Million PLN | 20.77% |
| 2009 FY | 6.37 Million PLN | 67.45% |
| 2008 FY | 3.8 Million PLN | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioceltix S.A. | - PLN | -Infinity% |
| BIOTON S.A. | 181.63 Million PLN | 94.584% |
| Captor Therapeutics Spolka Akcyjna | 13.2 Million PLN | 25.483% |
| Mabion S.A. | 151.67 Million PLN | 93.515% |
| Molecure S.A. | 100.00 PLN | -9836900.0% |
| NanoGroup S.A. | 2019.00 PLN | -487121.397% |
| Poltreg S.A. | 1.39 Million PLN | -603.145% |
| Pure Biologics Spólka Akcyjna | 95 Thousand PLN | -10254.737% |
| Ryvu Therapeutics S.A. | 46.86 Million PLN | 79.008% |
| Synthaverse S.A. | 58.6 Million PLN | 83.215% |
| Urteste S.A. | - PLN | -Infinity% |